COMMUNIQUÉS West-GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
17/10/2025
SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal [...]
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
17/10/2025
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients Vision improvements were seen in both pivotal studies, [...]
4DMT Announces New Employment Inducement Grants
17/10/2025
EMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
17/10/2025
Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class disease-modifying [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2025 it granted stock options to purchase an aggregate of 109,120 shares of [...]
Fagron’s share buy-back program: Weekly update
17/10/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 16 October 2025 through 17 October 2025, Fagron purchased [...]
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
17/10/2025
Provides clarity on the aspects to incorporate Company to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, [...]
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
17/10/2025
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and [...]
Wake Radiology Grows Breast Imaging Section with Five New Hires; Launches "We See the Difference" Campaign for Breast Cancer Awareness Month
17/10/2025
Raleigh, N.C., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex, the largest outpatient imaging provider in the Triangle, today announced the continued expansion of its breast imaging section with the [...]
RAMSAY SANTE : annual results at the end of June 2025
17/10/2025
PRESS RELEASE Paris, 17 th October 2025 Annual results at the end of June 2025 Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long term financing framework Activity growth [...]
RAMSAY SANTE : résultats annuels à fin juin 2025
17/10/2025
COMMUNIQUÉ DE PRESSE Paris, le 17 octobre 2025 Résultats annuels à fin juin 2025 Croissance du chiffre d'affaires de 4,7 % et EBITDA en hausse de 1,7 % malgré une baisse du financement public ; structure de financement [...]
Valitor Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer
17/10/2025
BERKELEY, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the appointment of Gregory D. Kunst as chief executive officer [...]
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
17/10/2025
Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a [...]
Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke
17/10/2025
Novel mechanism of action reverses and prevents death of injured cells Phase II ARPEGGIO trial fully enrolled Topline results to be presented at the World Stroke Congress, October 23, 2025 SOUTH SAN FRANCISCO, Calif., [...]
Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025
17/10/2025
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the [...]
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
17/10/2025
Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 ( ERBB2 )-mutant NSCLC were presented for the first [...]
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
17/10/2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with [...]
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
17/10/2025
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology, today announced its strategic initiative to redesign its corporate website and develop [...]
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
17/10/2025
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]

Pages